期刊
RHEUMATOLOGY INTERNATIONAL
卷 37, 期 6, 页码 999-1005出版社
SPRINGER HEIDELBERG
DOI: 10.1007/s00296-017-3720-7
关键词
Cohort; Fragile fracture; Osteoporosis; Inflammatory disease; Dual-energy X-ray absorptiometry
类别
资金
- AbbVie
- Astellas Pharma Inc.
- Bristol-Myers Squibb
- Chugai Pharmaceutical
- Eisai
- Janssen
- Lilly
- Mitsubishi Tanabe Pharma Corporation
- MSD
- Ono Pharmaceutical
- Pfizer
- Roche
- Takeda Pharmaceutical
- Teijin Pharma
- UCB
- Grants-in-Aid for Scientific Research [26462314] Funding Source: KAKEN
Although patients with rheumatoid arthritis (RA) are prone to osteoporosis, tight control of disease activity might have a positive effect on bone metabolism. We aimed to determine whether bisphosphonate use is still important to improve bone mineral density (BMD) in RA patients whose disease activity was tightly controlled and the dose of glucocorticoid was reduced. This study was a sub-analysis of the 10-year prospective cohort TOtal Management Of Risk factors in Rheumatoid arthritis patients to lOWer morbidity and mortality: the TOMORROW which started from 2010. We compared BMD between 192 patients with RA and age- and sex-matched volunteers between 2010 and 2013 using dual-energy X-ray absorptiometry (DXA) in whole body mode. We then determined ratios of changes in BMD (%Delta BMD) to assess factors influencing increases in BMD among the patients using multivariate logistic regression analysis. The BMD was significantly lower in the patients than in the controls at all sites surveyed during 2010 and 2013. The %Delta BMD of the total spine was significantly higher among the patients treated with, than without bisphosphonate (6.2 vs. 1.8%, P = 0.0001). Multivariate logistic regression analysis revealed that use of bisphosphonate was a significant factor contributing to BMD increase (odds ratio 2.13; 95% confidence interval, 1.03-4.38, P = 0.041). Meanwhile, use of biologic agents, reducing glucocorticoid dose, and control of disease activity were not significant factors for gain of BMD. The BMD was lower among patients with RA than non-RA controls. Use of bisphosphonate significantly increased the BMD of the spine in patients over a period of 3 years and was important for maintaining the BMD among patients with RA under the control of inflammation and disease activity.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据